

8-9 October 2024

18<sup>th</sup> EURL-AR Workshop




# Monitoring AMR in food-producing animals and food in the EU

-  
**2022 EUSR on AMR**

Raquel García Fierro

# 2022 EUSR on AMR : New Requirements in the new AMR legislation



<https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2024.8583>

Publication date: 28<sup>th</sup> of February 2024

## Data on AMR addressed

- AMR data received from 27 MSs, United Kingdom (Northern Ireland) and 4 non-Mss
- 2021 AMR from fattening pigs and calves and derived meat
- 2022 AMR data from poultry flocks and derived meat

## Commission Implementing Decision 2020/1729/EU

Lays down specific tech. requirements 2021 - 2027

- ➔ Mandatory AMR data for *Salmonella* spp. isolates from:
  - Samples of **caecal content** taken at **slaughter** for fattening pigs
  - Samples of **caecal content** taken at **slaughter** from bovine animals <1 year of age
- ➔ **Imported fresh meat at Border Control Post (BCPs) for *E.coli* & *Salmonella* (poultry meat)**
- ➔ New antimicrobial substances
  - **Amikacin** → *Salmonella* spp. and indicator *E.coli*
  - **Chloramphenicol** and **Ertapenem** → *Campylobacter* spp.
- ➔ WGS results







# AMR MONITORING

AMR monitoring is performed on a **biennial basis** and the **sampling in a rotating basis**

Good compromise between scientific needs and MSs capacities

- Harmonisation** contributes to representativeness and reliability of AMR data
- Harmonised Representative **Sampling Designs**
  - Harmonised **isolation and identification methods**
  - Harmonised **AST: microdilution**
  - Harmonised **Panels of Antimicrobials**
  - Harmonised Interpretative Criteria of Resistance: **ECOFFs**
  - Harmonised **WGS protocols** used on a voluntary basis in 2021 onwards



- Food-producing animals **most frequently consumed** in the EU
- Healthy** animals, domestically produced

The collection and reporting of data is performed at the **isolate level**

Antimicrobial Susceptibility Testing (AST) performed by **NRLs-AR** and other laboratories





***Salmonella spp.***



# 1. AMR - Salmonella spp.


## 1.1 Levels of resistance

- From low (laying hens) to high resistance to **AMP**, **SUL** and **TET**




- From moderate (laying hens, pigs and calves) to very high (broilers & turkeys) resistance to **flouoroquinolones (CIP)**
- Very low/low resistance to **third generation cephalosporins (CTX)** in animals
- From very low (pigs, turkeys and laying hens) to low (broilers and calves) **combined resistance to CIP/CTX**
- Very low resistance to **AMK** in all animal populations *and not detected in calves*

Occurrence of resistance in *Salmonella* spp., food-producing animals, 2021-2022  
Resistance to: AMP SMX TET CIP CTX CIP/CTX AMK




# 1. AMR - Salmonella spp.


## 1.2 Complete susceptibility (CS)



2022



2021



- ✓ **Marked variations** in the levels of **CS** between reporting countries, particularly in pigs and broilers and turkeys
- ✓ Generally, **CS** spanned **higher levels** among isolates from laying hens



# 1. AMR - *Salmonella* spp.

## 1.3 Phenotypic characterisation

### Resistance to 3rd Generation cephalosporins






- Presumptive ESBL- and/or AmpC-producers were observed at **very low levels** in pigs, and laying hens
- Presumptive ESBL and/or AmpC-producers were observed at **low levels** in broilers, turkeys and bovines

### Carbapenem resistance

In 2020 and 2021:

- **None of the *Salmonella* isolates recovered from any of the animal populations exhibited 'microbiological' resistance to meropenem**

**TABLE 6** Summary of the presumptive ESBL-, AmpC- or CP-producing *Salmonella* spp. from humans and food-producing animals, subjected to supplementary testing (panel 2) or whole genome sequencing, EU MSs, 2021–2022.

Matrix	ESBL and/or AmpC <sup>a</sup>	ESBL <sup>b</sup>	AmpC <sup>c</sup>	ESBL + AmpC <sup>d</sup>	CP <sup>e</sup>
	n (% R)	n (% R)	n (% R)	n (% R)	n (% R)
Humans 2021 (N=9787, 14 MSs)	88 (0.9)	76 (0.8)	12 (0.1)	0 (0)	0 (0)
Humans 2022 (N= 14,058, 26 MSs)	150 (1.1)	122 (0.9)	24 (0.2)	4 (<0.1)	4 (<0.1)
Fattening pigs, 2021 (N= 1258, 25 MSs+XI) 	11 (0.9)	9 (0.7)	0 (0)	2 (0.2)	0 (0)
Calves, 2021 (N=79, 10 MSs) 	2 (2.5)	1 (1.3)	0 (0)	1 (1.3)	0 (0)
Broilers, 2022 (N= 1911, 24 MSs+XI) 	26 (1.4)	26 (1.4)	0 (0)	0 (0)	0 (0)
Fattening turkeys, 2022 (N=686, 19 MSs) 	15 (2.2)	15 (2.2)	0 (0)	0 (0)	0 (0)
Laying hens, 2022 (N=908, 23 MSs+XI) 	2 (0.2)	2 (0.2)	0 (0)	0 (0)	0 (0)

Abbreviations: AmpC, AmpC beta- lactamase; CP, carbapenemase; ESBL, extended- spectrum beta- lactamase;

N, total number of isolates reported; n, number of isolates with the correspondent phenotype; %R, percentage of isolates resistant

<sup>a</sup> According to EUCAST guidelines (EUCAST, 2017), only isolates showing MIC > 1 mg/L for CTX and/or CAZ or reported presence of ESBL-/AmpC- encoding gene were considered (see Appendix F).

<sup>b</sup> All isolates showing clavulanate synergy with CTX or CAZ or both, suggesting ESBL phenotype, or reported presence of ESBL- encoding gene.

<sup>c</sup> Isolates with cefoxitin resistance, suggesting AmpC phenotype, or reported presence of AmpC- encoding gene.

<sup>d</sup> Isolates showing synergy with CTX or CAZ and cefoxitin resistance, suggesting ESBL- and AmpC- enzymes in the same isolates, or both ESBL- and AmpC- encoding genes reported.

<sup>e</sup> Isolates with meropenem resistance or CP- encoding gene reported.





# ***Campylobacter spp.***





# 2. AMR – *Campylobacter* spp.

## 2.1. Levels of resistance

- The level of overall resistance to **TET** ranged from **high** to **extremely high** in food-producing animals in *C. jejuni* and *C. coli*
- Very high** resistance levels to **CIP** in *C.jejuni* and *C.coli* in food-producing animals
- Resistance to **ERY** at **low** levels in *C.jejuni* in animals, while higher levels of resistance detected in *C. coli*


- Combined resistance to **CIP/ERY**:

**Rare to low** in *C. jejuni* from poultry, pigs and calves


**Low** in *C. coli* from pigs and broilers, and **moderate** in *C. coli* isolated from fattening turkeys and calves

- Resistance to **chloramphenicol** and **ertapenem** in isolates from pigs and calves was either **absent** or **very low**, except for an **unexpected higher level of resistance to ertapenem** reported in *C. coli* isolated from calves in 2021

*C. jejuni*




*C. coli*



## 2. AMR – *Campylobacter* spp.

### 2.2. MDR and CS

- **Multidrug resistance:** generally low for *C. jejuni* from animals, while it was markedly higher in *C. coli* isolated from calves, pigs and turkeys. These results agree with the higher levels of resistance to selected antimicrobials seen in *C. coli* isolates.
- Overall, **complete susceptibility** (i.e. defined in the report as susceptibility to CIP, ERY, TET and GEN) was higher in *C. jejuni* than in *C. coli* isolates in food-producing animals.





# ***Indicator E. coli***




# 3. AMR - Indicator *E.coli*

## 3.1 Levels of resistance

- **High** levels of resistance to commonly used antimicrobials (**AMP**, **SMX**, **TET**)
- **Important resistance** to fluoroquinolones (**CIP**) in broilers and turkeys
- Low resistance to cefotaxime (**CTX**)
- Combined resistance to **third-generation cephalosporins** and **fluoroquinolones** (**CIP/CTX**) was generally **uncommon** in all animal categories.
- Resistance to high priority critically important antimicrobials (**HPCIA**) was **uncommon** for **colistin** and **azithromycin**
- Very low levels of resistance to **AMK**



Occurrence of resistance in indicator commensal *E. coli* from food-producing animals, 2021-2022





# 3. AMR- Indicator *E.coli*

## 3.2 Complete susceptibility (CS)

2022



2021



- **CS** more common in **fattening pigs** and **calves** than in broilers and fattening turkeys
- **Marked variations between countries:** a North to South gradient / an East to West gradient

# 3. AMR- Indicator *E.coli*

## 3.2 Key Outcome indicator on Complete susceptibility ( $KOI_{CS}$ )


- Marked variations among the 28 reporting countries.
- **Lower  $KOI_{CS}$**  were generally observed in countries in **eastern and southern Europe** and the **highest** in countries in the northern Europe
- Levels of  $KOI_{CS}$  were:
  - <20% in six countries,
  - 20-40% in eleven countries,
  - 40-60% in seven countries,
  - 60-80% in two countries (FI, IS) and
  - >80% in two countries (SE, NO)
- Statistically significant **decreasing** trends in 3 countries
- Statistically significant **increasing** trends (from 2014-2022) in **18 countries** → **64% of reporting countries**



# 3. AMR- Indicator *E.coli*

## 3.2 Key Outcome indicator on prevalence of ESBL-/AmpC- *E.coli*

- Marked variations in the prevalence of presumptive ESBL and/or AmpC-producers among the 31 reporting countries
- **Lower  $KOI_{ESBL}$**  were generally observed in countries **in northern Europe** and the highest in countries in the eastern and southern Europe
- Levels of  $KOI_{ESBL}$  were:
  - <20% in nine countries,
  - 20-40% in five countries,
  - 40-60% in twelve countries,
  - 60-80% in four countries (SE) and
  - >80% no countries
- Statistically significant **increasing** trends in 3 countries
- Statistically significant **decreasing** trends in 23 countries → **77% of reporting countries**



**Genotypic data:**  
 Austria  
 Czechia  
 Germany  
 Finland  
 Italy  
 Ireland  
 Sweden

Trend (-18%)  
 ↓ EU Level



# 3. AMR- Indicator *E.coli*

## 3.2 Key Outcome indicators KOIs - Key messages

- **Increase** in the proportion of indicator *E. coli* exhibiting ‘**complete susceptibility**’ or ‘**zero resistance**’ to a harmonised set of important antimicrobials

From 2014-2022  
increasing trend in  
64% of the reporting  
countries

- A **decline** in the **prevalence of ESBL-/AmpC-producing *E. coli***

From 2015-2022  
decreasing trend in  
77% of the reporting  
countries

... reveal significant progress in the reduction of AMR in food-producing animals in several countries and in the EU group





# 4. AMR - ESBL and/or AMPC- producing *E.coli*

## 4.2 WGS results

Genotypic data from:


Austria  
Czechia  
Germany  
Finland  
Italy  
Ireland  
Sweden

Genotypic data reported


2021 → Provided by 4 MSs

2022 → Provided by 7 MSs

(A) Percentage of isolates with ESBL-encoding genes in food-producing animals, 2021-2022



(C) Percentage of isolates with AMPC-encoding genes in food-producing animals, 2021-2022





## ***CP-producers specific monitoring***



# 5. AMR – CP- producing *E.coli*

## 4.2 WGS results

### 4. Carbapenems a last resort antibiotics:

**Salmonella spp.:** Carbapenem-R was found in humans (4 confirmed isolates (*bla<sub>OXA-48</sub>*)) but **not** in food-producing animals

**E. coli:** Carbapenem-R was detected in food-producing animals

Occurrence of carbapenem-R is still reported at **very low** levels

### BUT

Presence of carbapenemase-producing bacteria in humans and in food-producing animals in

- Several countries
- Several animal species
- Several genes

... requires attention and further investigation

**Table 20:** Summary table on carbapenemase-encoding genes reported in *Escherichia coli* sampled in the routine monitoring, the specific monitoring of ESBL-/AmpC-/CP-producers and the specific monitoring of CP-producers in 2021 and 2022.

Year	Matrix	Gene	Number of isolates	Number of countries detecting the isolates
<b>Routine monitoring of indicator <i>E. coli</i></b>				
2022	Fattening turkeys	<i>bla<sub>OXA-181</sub></i>	1	1 (IT)
<b>Specific monitoring of ESBL-/AmpC-/CP-producing <i>E. coli</i></b>				
2021	Pig meat at retail	<i>bla<sub>NDM-5</sub></i>	1	1 (HU)
	Cattle meat at retail	<i>bla<sub>NDM-5</sub></i>	2	1 (HU)
2022	Broilers	<i>bla<sub>VIM-1</sub></i>	3	2 (AT, IT)
<b>Specific monitoring of CP-producing <i>E. coli</i></b>				
2021	Fattening pigs	<i>bla<sub>OXA-48</sub></i>	3	2 (ES, IT)
		<i>bla<sub>OXA-181</sub></i>	20	1 (IT)
		<i>bla<sub>NDM-5</sub></i>	3	1 (CZ)
	Cattle under one year of age	<i>bla<sub>NDM-5</sub></i>	1	1 (IT)
		<i>bla<sub>OXA-181</sub></i>	4	1 (IT)
2022	Fattening turkeys	<i>bla<sub>OXA-181</sub></i>	1	1 (IT)









# ***Online Visualisation tools***



# MODERNISATION - ONLINE VISUALISATION TOOLS: DASHBOARDS & STORY MAPS

- 2021 visualisation tools



- 2022 Visualisation tools



## Monitoring AMR in indicator *E. coli* (update)



**Thanks for your attention**

## **Acknowledgements**

**Members of the EFSA Scientific Network on for Zoonoses Monitoring Data**

**Members of the ECDC Food and Waterborne Diseases and Zoonoses Network,  
European Laboratory on Antimicrobial Resistance (EURL-AR)**

**EFSA staff members, ECDC staff members**

**EFSA's contractor: a consortium composed by SVA, DTU, NVI, Soladis and EFOR-CVO-Soladis**



# STAY CONNECTED

## SUBSCRIBE TO

[efsa.europa.eu/en/news/newsletters](https://efsa.europa.eu/en/news/newsletters)  
[efsa.europa.eu/en/rss](https://efsa.europa.eu/en/rss)  
[Careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



## LISTEN TO OUR PODCAST

Science on the Menu – Spotify, Apple Podcast and YouTube



## FOLLOW US ON TWITTER

[@efsa\\_eu](https://twitter.com/efsa_eu)                      [@methods\\_efsa](https://twitter.com/methods_efsa)  
[@plants\\_efsa](https://twitter.com/plants_efsa)                [@animals\\_efsa](https://twitter.com/animals_efsa)



## FOLLOW US ON LINKEDIN

[Linkedin.com/company/efsa](https://linkedin.com/company/efsa)



## FOLLOW US ON INSTAGRAM

[@one\\_healthenv\\_eu](https://instagram.com/one_healthenv_eu)



## CONTACT US

[efsa.europe.eu/en/contact/askefsa](https://efsa.europe.eu/en/contact/askefsa)

